Targets › GLOBOH
1 program from 1 company in 1 trial: 1 Phase 2; Oncology.
Open in Phaseline: the race on GLOBOH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| OBI Pharma | OBI-833/OBI-821 Globo H-targeting immunotherapy (cancer vaccine) | GLOBOH | Phase 2 | Non-small Cell Lung Cancer | – |
Non-small Cell Lung Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.